353 related articles for article (PubMed ID: 24772870)
1. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
2. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Karmiris K; Paintaud G; Noman M; Magdelaine-Beuzelin C; Ferrante M; Degenne D; Claes K; Coopman T; Van Schuerbeek N; Van Assche G; Vermeire S; Rutgeerts P
Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
[TBL] [Abstract][Full Text] [Related]
3. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
9. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
[TBL] [Abstract][Full Text] [Related]
10. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
13. [Adalimumab therapy in Crohn's disdease].
Baryshnikov EN; Lazebnik LB; Parfenov AI
Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
15. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
[No Abstract] [Full Text] [Related]
16. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
17. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
McDonnell MJ; Rutherford RM; O'Regan A
J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
[No Abstract] [Full Text] [Related]
18. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
19. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series.
Savarino E; Dulbecco P; Bodini G; Assandri L; Savarino V
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):468-70. PubMed ID: 22266834
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]